Pharmaceuticals (Nov 2020)
Introduction to “Immunotherapies for Multiple Myeloma”
Abstract
Multiple myeloma (MM) is the second most common hematological cancer after diffuse large B-cell lymphoma, accounting for about 10% of all blood cancers [...]
Keywords